X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6168) 6168
Publication (621) 621
Book Review (14) 14
Book Chapter (8) 8
Conference Proceeding (5) 5
Dissertation (3) 3
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3417) 3417
humans (2934) 2934
benzoquinones - pharmacology (2579) 2579
benzoquinones (2330) 2330
index medicus (1965) 1965
quinones - pharmacology (1676) 1676
mice (1506) 1506
male (1470) 1470
lactams, macrocyclic (1459) 1459
pharmacology & pharmacy (1268) 1268
rats (1241) 1241
biochemistry & molecular biology (1115) 1115
rifabutin - analogs & derivatives (1058) 1058
lactams, macrocyclic - pharmacology (1052) 1052
hsp90 heat-shock proteins - antagonists & inhibitors (916) 916
cell line, tumor (828) 828
enzyme inhibitors - pharmacology (825) 825
female (769) 769
hsp90 heat-shock proteins - metabolism (756) 756
benzoquinones - chemistry (689) 689
apoptosis (665) 665
oncology (639) 639
dose-response relationship, drug (615) 615
phosphorylation (614) 614
cells, cultured (597) 597
apoptosis - drug effects (594) 594
cell biology (584) 584
protein-tyrosine kinases - antagonists & inhibitors (545) 545
toxicology (545) 545
chemistry, medicinal (537) 537
activation (536) 536
cell line (525) 525
antineoplastic agents - pharmacology (522) 522
cancer (512) 512
expression (510) 510
hsp90 (501) 501
geldanamycin (478) 478
oxidative stress (448) 448
signal transduction (444) 444
benzoquinones - metabolism (436) 436
cell survival - drug effects (436) 436
heat shock proteins (429) 429
inhibition (416) 416
tumor cells, cultured (409) 409
kinetics (408) 408
oxidation-reduction (406) 406
proteins (394) 394
cells (382) 382
thymoquinone (381) 381
cell proliferation - drug effects (359) 359
signal transduction - drug effects (352) 352
time factors (329) 329
benzoquinones - therapeutic use (328) 328
in vitro techniques (322) 322
immunology (321) 321
analysis (320) 320
article (319) 319
research (314) 314
in-vitro (313) 313
blotting, western (309) 309
rats, wistar (304) 304
quinone (301) 301
toxicity (297) 297
molecular structure (296) 296
protein-tyrosine kinases - metabolism (290) 290
in-vivo (282) 282
structure-activity relationship (280) 280
rats, sprague-dawley (266) 266
quinones (256) 256
glutathione - metabolism (245) 245
liver - drug effects (243) 243
protein binding (242) 242
chemistry, multidisciplinary (237) 237
glutathione (232) 232
antibiotics, antineoplastic - pharmacology (230) 230
protein (227) 227
transfection (223) 223
biophysics (222) 222
antioxidants - pharmacology (213) 213
research article (211) 211
benzoquinone (210) 210
benzoquinones - administration & dosage (209) 209
growth (203) 203
benzoquinones - toxicity (202) 202
signal-transduction (200) 200
physiological aspects (199) 199
oxidative stress - drug effects (197) 197
cytotoxicity (194) 194
disease models, animal (194) 194
hsp90 heat-shock proteins - genetics (194) 194
reactive oxygen species - metabolism (189) 189
molecular sequence data (187) 187
antioxidants (186) 186
gene expression (186) 186
drug synergism (183) 183
enzyme activation (183) 183
phosphorylation - drug effects (182) 182
benzoquinones - isolation & purification (179) 179
metabolism (173) 173
mutation (172) 172
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5973) 5973
Japanese (81) 81
Chinese (45) 45
German (28) 28
Russian (27) 27
French (9) 9
Italian (4) 4
Spanish (2) 2
Ukrainian (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5686 - 5696
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non-small cell lung cancer... 
CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | NVP-TAE684 | ONCOLOGY | CERITINIB | EML4-ALK FUSION GENE | SENSITIVITY | CH5424802 | CRIZOTINIB RESISTANCE | NEUROBLASTOMA | IDENTIFICATION | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Lung Neoplasms - metabolism | Tomography, X-Ray Computed | Dose-Response Relationship, Drug | Piperidines - pharmacology | DNA Mutational Analysis | Inhibitory Concentration 50 | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Models, Molecular | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Protein Conformation | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carbazoles - pharmacology | Receptor Protein-Tyrosine Kinases - chemistry | gatekeeper mutation | crizotinib | ALK-rearranged NSCLC | alectinib (RO5424802 | resistance | ceritinib (LDK378)
Journal Article
Circulation, ISSN 0009-7322, 1998, Volume 97, Issue 1, pp. 99 - 107
Background-Vascular endothelial growth factor (VEGF), an endothelial cell mitogen that promotes angiogenesis, was initially identified as a vascular... 
Growth substances | Prostaglandins | Permeability | Nitric oxide | Endothelium | endothelium | nitric oxide | CARDIAC & CARDIOVASCULAR SYSTEMS | ANGIOGENESIS | TYROSINE KINASE | VEGF | permeability | FLT-1 | FACTOR RECEPTOR | MICROVASCULAR PERMEABILITY | LIMB | growth substances | BLOOD-VESSELS | prostaglandins | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | SMOOTH-MUSCLE CELLS | Endothelium, Vascular - cytology | Capillary Permeability - physiology | Vascular Endothelial Growth Factor A | Vascular Endothelial Growth Factors | Platelet Activating Factor - pharmacology | Rifabutin - analogs & derivatives | Capillary Permeability - drug effects | Nitrites - metabolism | Platelet Activating Factor - antagonists & inhibitors | Male | Endothelial Growth Factors - pharmacology | Microcirculation - drug effects | Epoprostenol - physiology | Lactams, Macrocyclic | Phenylephrine - pharmacology | Cattle | Histamine H1 Antagonists - pharmacology | Blood Pressure - drug effects | Lymphokines - pharmacology | Bradykinin - pharmacology | Quinones - pharmacology | NG-Nitroarginine Methyl Ester - pharmacology | Guinea Pigs | Histamine - pharmacology | Cells, Cultured | Enzyme Inhibitors - pharmacology | Nitric Oxide - physiology | Fibroblast Growth Factors - pharmacology | Benzoquinones | Pyridinium Compounds - pharmacology | Animals | Genistein - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Free Radical Biology and Medicine, ISSN 0891-5849, 2003, Volume 35, Issue 11, pp. 1500 - 1514
Journal Article
BMC Biology, ISSN 1741-7007, 03/2012, Volume 10, Issue 1, pp. 29 - 29
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2016, Volume 16, Issue 1, p. 458
Background: Endocannabinoids have recently drawn attention as promising anti-cancer agents. We previously observed that anandamide (AEA), one of the... 
DHEA | Head and neck cancer | Endocannabinoid | 5-lipoxygenase | NALA | ROS | CANCER-CELLS | APOPTOSIS | ACTIVATION | CYCLOOXYGENASE-2 | COX-2 | ANANDAMIDE | ENDOCANNABINOID SYSTEM | ACID METABOLISM | ONCOLOGY | CANNABINOIDS | MODULATION | Hydroxyurea - analogs & derivatives | Hydroxyurea - pharmacology | Phosphorylation | Alanine - therapeutic use | Reactive Oxygen Species - metabolism | Endocannabinoids - pharmacology | Apoptosis - drug effects | Humans | Antineoplastic Agents - therapeutic use | Carcinogenesis - metabolism | Organoselenium Compounds - pharmacology | Alanine - analogs & derivatives | TRPV Cation Channels - metabolism | Squamous Cell Carcinoma of Head and Neck | Piperidines - pharmacology | TRPV Cation Channels - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Alanine - pharmacology | Endocannabinoids - therapeutic use | Pyrazoles - pharmacology | Arachidonate 5-Lipoxygenase - metabolism | Signal Transduction | Head and Neck Neoplasms - drug therapy | Azoles - pharmacology | Arachidonic Acids - pharmacology | Benzoquinones - pharmacology | Receptor, Cannabinoid, CB1 - metabolism | Arachidonic Acids - therapeutic use | Carcinoma, Squamous Cell - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Lipoxygenase Inhibitors - pharmacology | Antioxidants | Squamous cell carcinoma | Care and treatment | Dehydroepiandrosterone | Dosage and administration | Research | Health aspects | Cancer
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2013, Volume 71, Issue 5, pp. 1325 - 1334
Sensitivity to a tyrosine kinase inhibitor (TKI) is correlated with the presence of somatic mutations that affect the kinase domain of epidermal growth factor... 
17-DMAG | Medicine & Public Health | Combination chemotherapy | Belinostat | Non-small cell lung cancer (NSCLC) | Oncology | Cancer Research | Tyrosine kinase inhibitor (TKI) | Pharmacology/Toxicology | EGFR | MOLECULAR CHARACTERIZATION | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | TYROSINE KINASE | ACQUIRED-RESISTANCE | RECEPTOR | EGFR KINASE DOMAIN | ONCOLOGY | IN-VIVO | GROWTH | PHARMACOLOGY & PHARMACY | MUTATIONS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Benzoquinones - administration & dosage | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Hydroxamic Acids - administration & dosage | Lactams, Macrocyclic - administration & dosage | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | PTEN Phosphohydrolase - genetics | Lactams, Macrocyclic - pharmacology | Sulfonamides - pharmacology | Benzoquinones - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Quinazolines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Epidermal growth factor | Nuclear radiation | Heat shock proteins | Lung cancer, Small cell | Universities and colleges | Lung cancer, Non-small cell | Gefitinib | Original
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 24, pp. 5772 - 5781
Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic endoplasmic reticulum (ER) stress, which is adaptively managed by... 
SURVIVAL | CELLS | IN-VITRO | UNFOLDED PROTEIN RESPONSE | PATHWAY | ER STRESS | BONE-MARROW | ENDOPLASMIC-RETICULUM STRESS | IDENTIFICATION | HEMATOLOGY | TRANSCRIPTION FACTOR | eIF-2 Kinase - metabolism | Humans | Pyrazines - therapeutic use | Endoribonucleases - antagonists & inhibitors | Boronic Acids - therapeutic use | RNA, Messenger - metabolism | X-Box Binding Protein 1 | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Multiple Myeloma - drug therapy | Enzyme Inhibitors - chemistry | RNA Splicing - genetics | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Stromal Cells - drug effects | Bone Marrow Cells - drug effects | Cell Death - drug effects | Protein-Serine-Threonine Kinases - metabolism | RNA Splicing - drug effects | Unfolded Protein Response - drug effects | Bortezomib | Endoplasmic Reticulum Stress - drug effects | Endoribonucleases - metabolism | Bone Marrow Cells - cytology | RNA, Messenger - genetics | Stromal Cells - metabolism | Enzyme Inhibitors - pharmacology | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Enzyme Activation - drug effects | Lactams, Macrocyclic - pharmacology | Enzyme Inhibitors - therapeutic use | Regulatory Factor X Transcription Factors | Benzoquinones - pharmacology | Multiple Myeloma - pathology | Animals | Interleukin-6 - pharmacology | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Pyrazines - pharmacology | Bone Marrow Cells - metabolism | Multiple Myeloma - genetics | Stromal Cells - cytology | Boronic Acids - pharmacology | Lymphoid Neoplasia
Journal Article